The safety of new drug treatments for idiopathic pulmonary fibrosis

Expert Opinion on Drug Safety

Volumn 15, Issue 11, 2016, Pages 1483-1489

  Fletcher, Sophie ^a   Jones, Mark G ^a,b   Spinks, Katherine ^a   Sgalla, Giacomo ^a,b   Marshall, Ben G ^a   Limbrey, Rachel ^a   Richeldi, Luca ^a,b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Idiopathic pulmonary fibrosis; nintedanib; pirfenidone; safety

Indexed keywords

NINTEDANIB; PIRFENIDONE; ENZYME INHIBITOR; INDOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; FIBROSING ALVEOLITIS; FOLLOW UP; HUMAN; PATIENT COUNSELING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; ANIMAL; IDIOPATHIC PULMONARY FIBROSIS; PATHOPHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ENZYME INHIBITORS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; PYRIDONES;

EID: 84992125528     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2016.1218470     Document Type: Review

References (44)

1. E.B.Meltzer, P.W.Noble Idiopathic pulmonary fibrosis. Orphanet J Rare Dis. 2008;3(1):8.
2. G.Raghu, H.R.Collard, J.J.Egan, et al. An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
3. M.G.Jones, S.Fletcher, L.Richeldi. Idiopathic pulmonary fibrosis:recent trials and current drug therapy. Respiration. 2013;86:353–363.
4. M.Selman, T.E.King, A.Pardo, et al. Idiopathic pulmonary fibrosis:prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134(2):136–151.
5. T.E.King, A.Pardo, M.Selman. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949–1961.
6. American Thoracic Society. Idiopathic pulmonary fibrosis:diagnosis and treatment. International consensus statement. Am Thorac Soc (ATS), Eur Respir Soc (ERS). 2000;161(2):646–664.
7. The Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–1977.
8. I.Noth, K.J.Anstrom, S.B.Calvert, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;186(1):88–95.
9. T.E.KingJr, K.K.Brown, G.Raghu, et al. BUILD-3:a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(1):92–99.
10. G.Raghu, J.Behr, K.K.Brown, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan:a parallel, randomized trial. Ann Intern Med. 2013;158(9):641–649.
11. G.Raghu, R.Million-Rousseau, A.Morganti, et al. Macitentan for the treatment of idiopathic pulmonary fibrosis:the randomised controlled MUSIC trial. Eur Resp J. 2013;42(6):1622–1632.
12. B.A.Karimi-Shah, B.A.Chowdhury. Forced vital capacity in idiopathic pulmonary fibrosis - FDA review of pirfenidone and nintedanib. N Engl J Med. 2015;372(13):1189–1191.
13. L.Richeldi, R.M.Bois Du, G.Raghu, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–2082.
14. T.E.KingJr, W.Z.Bradford, S.Castro-Bernardini, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–2092.
15. S.Nakayama, H.Mukae, N.Sakamoto, et al. Pirfenidone inhibits the expression of HSP47 in TGF-β1-stimulated human lung fibroblasts. Life Sci. 2008;82(3–4):210–217.
16. C.J.Schaefer, D.W.Ruhrmund, L.Pan, et al. Antifibrotic activities of pirfenidone in animal models. Eur Resp Rev. 2011;20(120):85–97.
17. B.Lee, S.Margolin, R.Nowak. Pirfenidone:a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocr Metab. 1998;83(1):219–223.
18. T.Kakugawa, H.Mukae, T.Hayashi, et al. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Resp J. 2004;24(1):57–65.
19. A.Azuma, T.Nukiwa, E.Tsuboi, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171(9):1040–1047.
20. H.Taniguchi, M.Ebina, Y.Kondoh, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Resp J. 2010;35(4):821–829.
21. P.W.Noble, C.Albera, W.Z.Bradford, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY):two randomised trials. Lancet. 2011;377(9779):1760–1769.
22. G.J.Roth, R.Binder, F.Colbatzky, et al. Nintedanib:from discovery to the clinic. J Med Chem. 2015;58(3):1053–1063.
23. L.Wollin, A.Pautsch, G.Schnapp, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1434–1445.
24. L.Wollin, I.Maillet, V.Quesniaux, et al. Anti-fibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor, nintedanib, in experimental models of lung fibrosis. J Pharmacol Exp Ther. 2014;349:209–220.
25. L.Richeldi, U.Costabel, M.Selman, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079–1087.
26. M.Kolb, L.Richeldi, T.Kimura, et al. Effect of baseline FVC on decline in lung function with nintedanib in patients with IPF:results from the INPULSIS® trials. Am J Respir Crit Care Med. 2015;191:A1021.
27. U.Costabel, Y.Inoue, L.Richeldi, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med. 2016;193(2):178–185.
28. G.Raghu, B.Rochwerg, Y.Zhang, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline:treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3–e19.
29. U.Costabel, C.Albera, A.Cohen, et al. The long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF):interim data from the RECAP extension study. Eur Resp J. 2011;38:174S.
30. L.Lancaster, C.Albera, W.Z.Bradford, et al. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis:integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir Res. 2016;3(1):e000105.•• A recent review of safety and tolerability of pirfenidone in IPF.
31. C.M.Rubino, S.M.Bhavnani, P.G.Ambrose, et al. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther. 2009;22(4):279–285.
32. U.Costabel, E.Bendstrup, V.Cottin, et al. Pirfenidone in idiopathic pulmonary fibrosis:expert panel discussion on the management of drug-related adverse events. Adv Ther. 2014;31(4):375–391.
33. Pirfenidone:Annex I:Summary of Product Characteristics. EMA product information. 2015; London:European Medicines Agency.•• EMA product information:updated information about safety of pirfenidone.
34. L.Richeldi, V.Cottin, R.M.Bois du, et al. Nintedanib in patients with idiopathic pulmonary fibrosis:combined evidence from the TOMORROW and INPULSIS® trials. Respir Med. 2016;113:74–79.
35. B.Crestani, T.Ogura, K.Pelling, et al. Safety and tolerability of nintedanib in patients with IPF:interim analysis from an open-label extension of the INPULSIS® trials (INPULSIS®-ON). Am J Respir Crit Care Med. 2015;191:A1020.
36. Nintedanib:Annex I:Summary of Product Characteristics. EMA product information. 2015; London:European Medicines Agency.•• EMA product information:updated information about safety of nintedanib.
37. M.Schmidinger. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl. 2013;11(2):172–191.
38. T.Corte, F.Bonella, B.Crestani, et al. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res. 2015;16:116.•• A comprehensive review of safety and tolerability of nintedanib in IPF.
39. N.Chaudhuri, A.Duck, R.Frank, et al. Real world experiences:pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir Med. 2014;108(1):224–226.
40. R.Okuda, E.Hagiwara, T.Baba, et al. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med. 2013;107(9):1431–1437.
41. V.Cottin, T.Maher. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015;24:58–64.
42. S.Harari, A.Caminati, C.Albera, et al. Efficacy of pirfenidone for idiopathic pulmonary fibrosis:an Italian real life study. Respir Med. 2015;109:904–913.
43. S.V.Fletcher, M.G.Jones, E.Renzoni, et al. Nintedanib for the treatment of idiopathic pulmonary fibrosis – initial clinical experience in a UK cohort. Thorax. 2015;70(Suppl 3):A78.
44. A.Ogura, H.Taniguchi, A.Azuma, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Resp J. 2015;45(5):1382–1392.